Endocrine, Physiology, USMLE Step 1 - Full Vignette with Extended Explanations

Описание: A 45-year-old woman with a confirmed MEN1 pathogenic variant presents for surveillance counseling, reporting a history of nephrolithiasis and intermittent heartburn. Family history is notable for early-onset hypercalcemia and pancreatic neuroendocrine tumor. Her labs reveal elevated serum calcium with high PTH, and imaging finds a pituitary microadenoma. What patterns of age-related endocrine tumor development should influence your surveillance approach in midlife patients with MEN1 mutations?

VIDEO INFO
Category: Endocrine, Physiology, USMLE Step 1
Difficulty: Moderate - Intermediate level - Requires solid foundational knowledge
Question Type: Epidemiology
Case Type: Tricky Findings

Explore more ways to learn on this and other topics by going to https://endlessmedical.academy/auth?h...

QUESTION
A 45-year-old woman with a germline MEN1 pathogenic variant confirmed by next-generation sequencing presents for surveillance counseling. She reports intermittent heartburn and a history of nephrolithiasis in her twenties. She smokes 0.5 pack/day for 5 years and uses marijuana daily; she drinks 1-2 alcoholic beverages per week. She owns dogs and reports soy allergy with hives and mold allergy with cough. She works in food service....

OPTIONS
A. Primary hyperparathyroidism approaches near-universal penetrance by age 50 years in MEN1, and duodenopancreatic and pituitary tumors are also common; parathyroid disease is typically multiglandular and is the earliest and most frequent manifestation.
B. Hyperparathyroidism is rarely seen by age 50 years in MEN1, whereas medullary thyroid carcinoma dominates the phenotype, so prophylactic thyroidectomy is the central surveillance strategy.
C. Pheochromocytoma is the most prevalent endocrine tumor in MEN1 by midlife, greatly exceeding pituitary and pancreatic neuroendocrine tumor risk and warranting annual plasma metanephrines as the primary focus.
D. Overall MEN1 penetrance remains below 20% by age 40 and only modestly increases by age 50, so intensive biochemical and imaging surveillance can generally be deferred until late adulthood.

CORRECT ANSWER
A. Primary hyperparathyroidism approaches near-universal penetrance by age 50 years in MEN1, and duodenopancreatic and pituitary tumors are also common; parathyroid disease is typically multiglandular and is the earliest and most frequent manifestation.

EXPLANATION
"Primary hyperparathyroidism approaches near-universal penetrance by age 50 years in MEN1, and duodenopancreatic and pituitary tumors are also common; parathyroid disease is typically multiglandular and is the earliest and most frequent manifestation." - This is correct because MEN1 manifests first and most consistently with multiglandular primary hyperparathyroidism, with penetrance approaching unity by midlife. The patient already has hypercalcemia with inappropriately elevated PTH and nephrolithiasis history, consistent with early MEN1 parathyroid disease. Teaching point: surveillance emphasis by age 50 prioritizes parathyroid disease, while also screening for duodenopancreatic NETs and pituitary tumors.

"Hyperparathyroidism is rarely seen by age 50 years in MEN1, whereas medullary thyroid carcinoma dominates the phenotype, so prophylactic thyroidectomy is the central surveillance strategy." - Medullary thyroid carcinoma is characteristic of MEN2, not MEN1; prophylactic thyroidectomy is not an MEN1 strategy....


Further reading:

Links to sources are provided for optional further reading only. The questions and explanations are independently authored and do not reproduce or adapt any specific third-party text or content.

---------------------------------------------------

Our cases and questions come from the https://EndlessMedical.Academy quiz engine - multi-model platform. Each question and explanation is forged by consensus between multiple top AI models (i.e. Open AI GPT, Claude, Grok, etc.), with automated web searches for the latest research and verified references. Calculations (e.g. eGFR, dosages) are checked via code execution to eliminate errors, and all references are reviewed by several AIs to minimize hallucinations.

Important note: This material is entirely AI-generated and has not been verified by human experts; despite stringent consensus checks, perfect accuracy cannot be guaranteed. Exercise caution - always corroborate the content with trusted references or qualified professionals, and never apply information from this content to patient care or clinical decisions without independent verification.

Clinicians already rely on AI and online tools - myself included - so treat this content as an additional focused aid, not a replacement for proper medical education. Visit https://endlessmedical.academy for more AI-supported resources and cases.

This material can not be treated as medical advice. May contain errors.

---------------------------------------------------